Nov 1, 2021 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
Sep 23, 2021 By sarahjibrin HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern
Aug 9, 2021 By sarahjibrin HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline
Jun 17, 2021 By sarahjibrin FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
Jun 14, 2021 By sarahjibrin HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic
Jun 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy
May 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody
Apr 12, 2021 By sarahjibrin Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
Apr 12, 2021 By sarahjibrin HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
